Nano-X Imaging
NNOX · NASDAQ · Healthcare
$0.70
$0.04 (-5.32%) today
Market Cap
$54.84M
24h Volume
$734.2K
P/E Ratio
-4.4
52w High
$4.55
52w Low
$0.69
Est. AI Revenue
30%
7-Day Sparkline (Static)
Company facts
Performance
About Nano-X Imaging
Nano-X Imaging is a medical imaging company working to make X-ray imaging cheaper and more widely available. It sells low-cost digital X-ray systems to imaging providers and pairs them with AI software that reads the scans.
The AI is central to the offer. Nanox.AI and its automated disease detection flag findings in medical scans, the AI radiology assistant supports clinicians reviewing images, and Nanox.CLOUD connects imaging hardware, AI analysis, and radiologists in one workflow.
Founded in 2012 and headquartered in Neve Ilan, Israel, Nano-X trades on the NASDAQ and runs with a small team of about 200 people under CEO Erez Meltzer.
Nano-X Imaging in the AI buildout
Nano-X sits in the AI Healthcare layer, pairing affordable imaging hardware with AI that reads scans at scale. The thesis leans heavily on adoption of its AI radiology offering: if providers embrace automated disease detection on its systems, AI becomes the product, not a feature. The company is still small and early in proving that model commercially, which tempers the rating. Supercycle scores it 40 out of 100.
NNOX is tracked in AI Healthcare, rated Growing on the AI Exposure leaderboard.
By the numbers
52-week range
NNOX trades at $0.70, 0% of the way up its 52-week range of $0.69 to $4.55.
Market cap
Market capitalization is $54.84M, with an AI Exposure Score of 40 out of 100.
Next earnings
Nano-X Imaging is next expected to report earnings on November 19, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Nano-X Imaging do?
Nano-X sells low-cost digital X-ray systems paired with AI software that flags disease in scans, aiming to make medical imaging more affordable and accessible for providers.
How is Nano-X exposed to AI?
Substantially. Its thesis depends on adoption of its AI radiology software alongside its hardware, though the company is still early commercially. Supercycle scores it 40 out of 100.
What are Nano-X's main AI products?
Nanox.AI for automated disease detection in scans, an AI radiology assistant for clinicians, and Nanox.CLOUD, which connects imaging hardware, AI analysis, and radiologists.
Where is Nano-X headquartered and who leads it?
Nano-X is headquartered in Neve Ilan, Israel, was founded in 2012, and is led by CEO Erez Meltzer. It runs with a small team of about 200 people and trades on the NASDAQ.
Is NNOX a pure play AI stock?
Not quite. AI radiology is central to its offer, but it is an imaging hardware and software company still proving commercial traction. Supercycle scores it 40 out of 100.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.